WeTrials
Active, not recruiting

A Phase I, Multicenter, Open-label, First-in-Human, Dose Escalation and Expansion Study of AZD9592 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumors

What is this study?

This study is testing a new experimental cancer drug called AZD9592, both on its own and combined with other known anti-cancer medications. Researchers want to find the safest and most effective dose for adults with advanced solid tumors, including lung, head and neck, and colorectal cancers.

Who can participate?

Adults aged 18 and older who have advanced solid tumors and are strong enough to carry out daily activities can join. Participants need to meet specific health requirements regarding organ function and overall health history.

What will happen?

Participants will receive the study medication, either alone or with other cancer treatments, while doctors closely monitor their safety and how their body reacts to the drug. You will have regular check-ups and scans to see how well the treatment is working against the tumor.

Where and when?

The study is taking place at select medical centers in California, Connecticut, and Washington D.C. Currently, this study is active but not recruiting new participants.

Key Points
  • 1Tests a new experimental cancer therapy called AZD9592
  • 2Evaluates safety and effectiveness both alone and with other drugs
  • 3Focused on adults with advanced solid tumors like lung or colon cancer

No related links yet

Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Advanced Solid TumoursCarcinoma Non-small Cell LungHead and Neck NeoplasmsColorectal Neoplasms

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.